Cervical cancer screening by molecular Pap-transformation of gynecologic cytology.


Journal

Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895

Informations de publication

Date de publication:
May 2019
Historique:
received: 24 07 2018
revised: 21 09 2018
accepted: 22 10 2018
pubmed: 24 11 2018
medline: 17 7 2019
entrez: 24 11 2018
Statut: ppublish

Résumé

Cervical cancer is one of the common cancers in women accounting for 7.9% of all cancers. In India it is the second commonest cancer in women. The immortality of the cancer cell and the relatively long time frame from acquisition of infection to development of cervical cancer was established. As major advancements like LBC, HPV testing were introduced in the recent years, screening has taken a new avatar, the Molecular pap!! The objectives of this study were: To compare gynecologic cytology and abnormal results with respect to conventional and LBC. To study the role of HPV cotesting and ancillary tests performed, that is, HPV CISH, and p16ink4a by IHC. About 71 924 Conventional and LBC samples were included from August 2009 to December 2017. Cases for HPV testing along the conventional smears were 1539. HPV can be tested from the same LBC vial as the sample remains stable at room temperature for 6 weeks. HPV DNA PCR was carried out in our laboratory for High and Low risk genotypes. Cytology findings were also correlated with histology. Detection rate of SILs in LBC samples were higher (2.20%). The commonest abnormality was LSIL in LBC and ASCUS in conventional smears. Commonest HR HPV and LR HPV detected was 1 61 856 and 61 142. LBC with HPV cotesting improves sensitivity and specificity and reduces ambiguous results; allows better compliance, as a negative result of both tests allows patients to get screening every 5 years, thereby increasing screening intervals, important in a resource limited situation.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer is one of the common cancers in women accounting for 7.9% of all cancers. In India it is the second commonest cancer in women. The immortality of the cancer cell and the relatively long time frame from acquisition of infection to development of cervical cancer was established. As major advancements like LBC, HPV testing were introduced in the recent years, screening has taken a new avatar, the Molecular pap!! The objectives of this study were: To compare gynecologic cytology and abnormal results with respect to conventional and LBC. To study the role of HPV cotesting and ancillary tests performed, that is, HPV CISH, and p16ink4a by IHC.
METHODS METHODS
About 71 924 Conventional and LBC samples were included from August 2009 to December 2017. Cases for HPV testing along the conventional smears were 1539. HPV can be tested from the same LBC vial as the sample remains stable at room temperature for 6 weeks. HPV DNA PCR was carried out in our laboratory for High and Low risk genotypes. Cytology findings were also correlated with histology.
RESULTS RESULTS
Detection rate of SILs in LBC samples were higher (2.20%). The commonest abnormality was LSIL in LBC and ASCUS in conventional smears. Commonest HR HPV and LR HPV detected was 1 61 856 and 61 142.
CONCLUSION CONCLUSIONS
LBC with HPV cotesting improves sensitivity and specificity and reduces ambiguous results; allows better compliance, as a negative result of both tests allows patients to get screening every 5 years, thereby increasing screening intervals, important in a resource limited situation.

Identifiants

pubmed: 30468313
doi: 10.1002/dc.24116
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

374-381

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Shaikhali M Barodawala (SM)

Department of Surgical Pathology & Molecular Biology, Integrated Oncopathology, Metropolis Healthcare Ltd, Mumbai, Maharashtra, India.

Kirti Chadha (K)

Department of Surgical Pathology & Molecular Biology, Integrated Oncopathology, Metropolis Healthcare Ltd, Mumbai, Maharashtra, India.

Vikas Kavishwar (V)

Department of Surgical Pathology & Molecular Biology, Integrated Oncopathology, Metropolis Healthcare Ltd, Mumbai, Maharashtra, India.

Anuradha Murthy (A)

Department of Surgical Pathology & Molecular Biology, Integrated Oncopathology, Metropolis Healthcare Ltd, Mumbai, Maharashtra, India.

Shamma Shetye (S)

Department of Molecular Biology, Metropolis Healthcare Ltd, Mumbai, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH